Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bromocriptine (National Institute of Cardiology)
- Development stage
- Approved
- Lead developer
- National Institute of Cardiology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bromocriptine is a semi-synthetic ergot alkaloid derivative that acts as a potent dopamine D2 receptor agonist and a partial D1 receptor antagonist. Traditionally indicated for the treatment of Parkinson's disease, hyperprolactinemia-associated dysfunctions (such as amenorrhea and infertility), and acromegaly, it has more recently been investigated for its role in peripartum cardiomyopathy (PPCM). In PPCM, bromocriptine is used to suppress prolactin secretion from the pituitary gland. This therapeutic approach is based on the pathophysiology where oxidative stress leads to the cleavage of the 23-kDa prolactin molecule into a 16-kDa fragment that is angiostatic and pro-apoptotic, causing myocardial damage. The PolBrom-PPCM trial, conducted by the Cardinal Stefan Wyszyński Institute of Cardiology, specifically evaluates the efficacy of intensified bromocriptine dosing regimens in improving left ventricular recovery in affected women.
- Brand names
- BromocornParlodelCyclosetBromergon
- Other names
- bromocriptine mesylate2-Bromo-alpha-ergocryptine
02
Targets
DRD1 (Dopamine D1 Receptor)5-HT (Serotonin receptors)DRD2 (Dopamine D2 Receptor)AR (Adrenergic receptors)
Beyond the preview
Go deeper on bromocriptine (National Institute of Cardiology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bromocriptine (National Institute of Cardiology).